DNA

First Tech Federal Credit Union Bolsters Support of Children’s Miracle Network Hospitals, Launches Java4Kids Program

Retrieved on: 
Tuesday, April 9, 2024
Other Professional Services, Other Health, Technology, Socially Responsible Investing, Finance, Fintech, Professional Services, General Health, Philanthropy, Hospitals, Children, Foundation, Other Philanthropy, Consumer, Health, Hospital, Friends, Partnership, Hillsboro School District, Civil Service (United Kingdom), Coffee, DNA, First, CMN, Multimedia, Credit union, CFIS, GroundUP

View the full release here: https://www.businesswire.com/news/home/20240409126482/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240409126482/en/
    Headquartered in Hillsboro, Oregon, First Tech has nearly $17 billion in assets and more than 660,000 members.
  • The credit union is one of the founders of CU4Kids , which brings together credit unions and business partners from across the country to raise funds for CMN Hospitals.
  • The credit union operates a coffee shop, Ground Up, that is completely run by local high school students.
  • "We are deeply humbled by the opportunity to partner with First Tech to support the Ground Up coffee shop and raise donations through Java4Kids at First Tech.

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Retrieved on: 
Monday, April 8, 2024
Health, Radiology, Pharmaceutical, Clinical Trials, Oncology, Toxicity, Therapy, Neoplasm, AACR, DNA, Prostate cancer, PSMA, MEK, Pharmaceutical industry

Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced results from a series of preclinical analyses designed to identify synergistic combinations of known anticancer drugs with 177Lu-rhPSMA-10.1 radioligand therapy, and from a preclinical efficacy analysis of the lead novel drug combination for the treatment of prostate cancer.

Key Points: 
  • Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced results from a series of preclinical analyses designed to identify synergistic combinations of known anticancer drugs with 177Lu-rhPSMA-10.1 radioligand therapy, and from a preclinical efficacy analysis of the lead novel drug combination for the treatment of prostate cancer.
  • “Combination approaches are of increasing interest among the medical community, as we know tumors are heterogeneous and some prostate cancer cells do not express PSMA.
  • Results from this preclinical study presented at AACR demonstrated a synergistic therapeutic effect between 177Lu-rhPSMA-10.1 and an MEK inhibitor.
  • This may be due to inhibition of the MEK-MAPK pathway during DNA damage response, resulting in radiosensitization of cancer cells to 177Lu-rhPSMA-10.1.

Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Oncology, Medical Devices, Health, Genetics, Clinical Trials, Biotechnology, Survival, Patient, RNA, DNA, Cancer, University, Biology, Woman, AACR, Catalog, Breast cancer, MRD, DCIS, Blood, Medical imaging

Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.

Key Points: 
  • Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.
  • In addition, the study showed the platform’s unique capability to distinguish low grade, less aggressive DCIS from invasive breast cancer with 87% sensitivity, at 90% specificity using a standard blood sample.
  • These results suggest the potential for Exai's platform to aid in tailoring adjuvant treatment for individual triple negative breast cancer patients.
  • oncRNAs are actively secreted from living cancer cells and are stable and abundant in the blood of cancer patients.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
Monday, April 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Survival, A-DNA, Patient, Neoplasm, DNA, Biology, AACR, Clinical trial, Skin, Medical imaging

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • BBI-355 is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTENTIATE clinical trial in patients with oncogene amplified cancers.
  • “Extrachromosomal DNA afford unique advantages to tumors, typically rendering existing therapies ineffective and correlating with poor patient outcomes,” said Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio.
  • BBI-355 showed substantial antitumor activity, including complete and durable regressions, in preclinical oncogene amplified models.

Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma

Retrieved on: 
Sunday, April 7, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Bone marrow, CDK7, MDM2, Apoptosis, BH3, CDK, AML, Dana–Farber Cancer Institute, Patient, LPS, Neoplasm, DNA, Cancer, Liposarcoma, Clinical trial, Azacitidine, CDK9, MCL1, Vaccine

The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.

Key Points: 
  • The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.
  • The data demonstrate that BTX-A51 has preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1α and CDK9.
  • “Dedifferentiated liposarcomas (DDLPS) are rare tumors derived from precursors of fat cells which can occur anywhere in the body.
  • Importantly, preliminary in vivo data in an LPS patient-derived xenograft model reveal that BTX-A51 is well-tolerated under conditions that inhibit tumor growth.

Announcing the 2024 Sun Valley Forum: Restoring Harmony With Nature

Retrieved on: 
Tuesday, April 9, 2024
Capacity building, Indigenous peoples, DNA, Forum, Mission blue butterfly, Carbon, GWMP, CO2, Coal, United Nations Environment Programme, Government, Management

KETCHUM, Idaho, April 9, 2024 /PRNewswire/ -- The ninth annual Sun Valley Forum, "Restoring Harmony With Nature," will be held from July 15 to July 18, 2024, at the Argyros Performing Arts Center in Ketchum, Idaho. The Forum is hosted by Christensen Global, a Ketchum-based sustainability advisory firm and the Sun Valley Institute for Resilience. 

Key Points: 
  • Leaders and Innovators to Gather for the Sun Valley Forum July 15-18, 2024
    KETCHUM, Idaho, April 9, 2024 /PRNewswire/ -- The ninth annual Sun Valley Forum , "Restoring Harmony With Nature," will be held from July 15 to July 18, 2024, at the Argyros Performing Arts Center in Ketchum, Idaho.
  • The Forum is hosted by Christensen Global, a Ketchum-based sustainability advisory firm and the Sun Valley Institute for Resilience .
  • The Sun Valley Forum advances to restore planetary health and resilience by convening global leaders and innovators from business, government, philanthropy, finance, Indigenous Peoples, and storytellers.
  • Our stewardship of nature is best informed by Indigenous Peoples who have stewarded nature for millennia," said Aimée Christensen, Sun Valley Forum curator.

Genomics plc and MassMutual's program enables more policyowners to understand health risks through innovative genetic testing

Retrieved on: 
Tuesday, April 9, 2024
Health, MassMutual, Cardiovascular disease, Face, Prostate cancer, Learning, Disease, Partnership, Atrial fibrillation, Diabetes, Genetics, Risk, Patient, Ageing, DNA, Breast, Insurance, Risk assessment, Privacy, Nursing

OXFORD, England and SPRINGFIELD, Mass., April 9, 2024 /PRNewswire/ -- Genomics plc (Genomics), a healthcare company transforming health through the power of genomics, and MassMutual, a leading mutual life insurance company in the United States, today announced the next phase of their innovative partnership enabling more eligible MassMutual policyowners to gain knowledge about their health in order to make informed, proactive decisions that may help them lead longer, healthier lives. The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases. The expansion follows a successful research collaboration in which more than 70% of policyowners who elected to use the risk assessment service reported intent to take preventative actions based on their risk scores, including plans to see their doctor or seek further screening.

Key Points: 
  • The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases.
  • Genomics' at-home test studies millions of small variations in DNA, generating polygenic risk scores, that can inform the likelihood of certain conditions.
  • During the initial Genomics and MassMutual research collaboration, 1 in 5 policyowners learned that they are at a higher risk for preventable diseases.
  • MassMutual only receives high-level, anonymized data from Genomics that allows the company to better understand aggregate policyowners' health and behaviors and interest in these types of offerings.

LG Innotek CEO Moon Hyuksoo aims to be the top in ADAS sensing by using 'High Performance LiDAR'.

Retrieved on: 
Tuesday, April 9, 2024
LG Corporation, RADAR, Shortwave radio, Pedestrian, Infrared, Light, Electronics, DNA, ADAS, 3D, Advanced driver-assistance system, Argo AI, SWIR, Multimedia, Snow, Movement, Engineering, Weather, Surveying

On the 9th, LG Innotek (CEO Moon Hyuksoo) announced that they developed a 'high-performance LiDAR' by tripling its detection range in worsening weather conditions.

Key Points: 
  • On the 9th, LG Innotek (CEO Moon Hyuksoo) announced that they developed a 'high-performance LiDAR' by tripling its detection range in worsening weather conditions.
  • Thus, it is praised as having the highest performance among sensing components for vehicles.
  • To achieve this performance, LG Innotek applied shortwave infrared rays instead of near-infrared rays used in conventional LiDARs.
  • Last year, LG Innotek acquired 77 US patents related to LiDAR from 'Argo AI,' an autonomous driving startup company specializing in LiDAR.